About us
Founded in 2012 and granted the qualification of biomedicine company by the Ministry of Economic Affairs in 2015, Energenesis Biomedical Co., Ltd. aspires to become a new star in biotech industry.
Information
- 2024-01 Orphan Drug Designation Granted to ENERGI-F703EB by the Committee for Orphan Medicinal Products(COMP) of the European Medicines Agency (EMA)
- 2023-07 Energenesis Biomedical has jointly signed a technical service contract with National Taiwan University and Yen Ching Ling Industrial Development Found
- 2023-07 Our invention patent for "Compound Activating AMPK and its Use" for the treatment of prediabetes and type 2 diabetes has been approved in Ca
- 2023-06 ENERGI-F703 diabetic foot ulcer topical gel has received approval from the Taiwan Food and Drug Administration (TFDA) to initiate Phase III clinical t
-
2023-06
Announcement: Energenesis Biomedical has signed a Memorandum of Understanding (MOU) with Healiva SA, a company ba
sed in Switzerland, to establish a